<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111889">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01647217</url>
  </required_header>
  <id_info>
    <org_study_id>P012-01</org_study_id>
    <secondary_id>2R44EY019586-02</secondary_id>
    <nct_id>NCT01647217</nct_id>
  </id_info>
  <brief_title>Demodex Blepharitis Treatment Study</brief_title>
  <acronym>DBTS</acronym>
  <official_title>Safety and Efficacy of Single-use Terpinen-4-ol Pads for Treating Ocular Mites A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tissue Tech Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Tissue Tech Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized clinical trial to determine the safety and efficacy of terpinen-4-ol
      (T4O), the most active ingredient of tea tree oil (TTO), in eradicating ocular demodicosis
      (reducing ocular demodex counts and achieving the clinical improvement with minimal or no
      irritation).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Demodex blepharitis is one of the most common causes of chronic blepharitis. The
      investigators preliminary clinical study showed that lid scrub with TTO was effective in
      resolving chronic blepharoconjunctivitis; however, it was not convenient for
      self-administration and caused irritation in some patients. Preclinical safety studies have
      verified that T4O is less irritant. In this study, the investigators will determine the
      optimal regimen of T4O Pads.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication of Demodex Mites</measure>
    <time_frame>4 months</time_frame>
    <description>Reduction in mites count after treatment compared to the baseline data. If the mites' count remains zero during the last two visits, it is considered &quot;complete eradication&quot;. Patients without achieving complete eradication will be categorized as &quot;incomplete eradication&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Lid Margin redness and Bulbar Conjunctival Hyperemia</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>Lid margin redness and bulbar conjunctival hyperemia will be assessed using an ordered categorical value ranging from 0 (None) to 3 (Severe). Hyperemia will be graded on the following scale and half scores are acceptable:
None (0) = normal
Mild (1) = Slight localized injection
Moderate (2) = pink color
Severe (3) = dark redness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Blepharitis</condition>
  <arm_group>
    <arm_group_label>Terpinen-4-ol Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 patients will be randomized into the Study Group and will be subdivided into 2 subgroups (15 patients each) according to the treatment regimen (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placepo Pads Contol Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 patients will be randomized into the control group and will be treated with placebo pads. They will be divided into 2 subgroups (15 each) according to the frequency (once or twice per day). Changes in the mite counts will be correlated with changes in symptoms and signs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terpinen-4-ol</intervention_name>
    <description>Lid scrub once or twice per day for one month.</description>
    <arm_group_label>Terpinen-4-ol Treatment Arm</arm_group_label>
    <other_name>T4O</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lid scrub once or twice per day for one month</description>
    <arm_group_label>Placepo Pads Contol Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with symptomatic Demodex blepharitis for duration of at least 3 months.

          -  Age range: 15-80 years old.

          -  Both genders and all ethnic groups comparable with the local community.

          -  Able to understand and willing to sign a written informed consent

          -  Able and willing to cooperate with the investigational plan.

          -  Able and willing to complete all mandatory follow-up visits.

        Exclusion Criteria:

          -  Patients who are currently engaged in another clinical trial, unwilling or unable to
             give consent, to accept randomization, or to return for scheduled visits.

          -  Children under 15.

          -  Pregnant women or expecting to be pregnant during the study.

          -  Systemic immune deficient conditions such as AIDS or under systemic
             immunosuppressant.

          -  Concomitant use of ophthalmic topical medications (excluding non-preserved tear
             substitutes).

          -  Concomitant use of systemic antibiotics or steroids.

          -  Contact lens wear (unless discontinued for â‰¥ 30 days before randomization)

          -  Active ocular infection or allergy

          -  Unable to close eyes or uncontrolled blinking

          -  Presence of aqueous tear deficient dry eye defined by the Fluorescein Clearance Test
             as less than 3 mm wetting in 1-minute Schirmer test with anesthesia.

          -  Previous allergic reaction to TTO-containing products or cosmetic fragrance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scheffer CG Tseng, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tissue Tech Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hosam El Sheha, MD, PhD</last_name>
    <phone>305-274-1299</phone>
    <email>hoss88@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ocular Surface Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hosam El Sheha, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Scheffer CG Tseng, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hosam El Sheha, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gao YY, Di Pascuale MA, Li W, Liu DT, Baradaran-Rafii A, Elizondo A, Kawakita T, Raju VK, Tseng SC. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3089-94.</citation>
    <PMID>16123406</PMID>
  </reference>
  <reference>
    <citation>Gao YY, Di Pascuale MA, Li W, Baradaran-Rafii A, Elizondo A, Kuo CL, Raju VK, Tseng SC. In vitro and in vivo killing of ocular Demodex by tea tree oil. Br J Ophthalmol. 2005 Nov;89(11):1468-73.</citation>
    <PMID>16234455</PMID>
  </reference>
  <reference>
    <citation>Gao YY, Di Pascuale MA, Elizondo A, Tseng SC. Clinical treatment of ocular demodecosis by lid scrub with tea tree oil. Cornea. 2007 Feb;26(2):136-43.</citation>
    <PMID>17251800</PMID>
  </reference>
  <reference>
    <citation>Kheirkhah A, Casas V, Li W, Raju VK, Tseng SC. Corneal manifestations of ocular demodex infestation. Am J Ophthalmol. 2007 May;143(5):743-749. Epub 2007 Mar 21.</citation>
    <PMID>17376393</PMID>
  </reference>
  <reference>
    <citation>Kheirkhah A, Blanco G, Casas V, Tseng SC. Fluorescein dye improves microscopic evaluation and counting of demodex in blepharitis with cylindrical dandruff. Cornea. 2007 Jul;26(6):697-700.</citation>
    <PMID>17592319</PMID>
  </reference>
  <reference>
    <citation>Li J, O'Reilly N, Sheha H, Katz R, Raju VK, Kavanagh K, Tseng SC. Correlation between ocular Demodex infestation and serum immunoreactivity to Bacillus proteins in patients with Facial rosacea. Ophthalmology. 2010 May;117(5):870-877.e1. doi: 10.1016/j.ophtha.2009.09.057. Epub 2010 Jan 15.</citation>
    <PMID>20079929</PMID>
  </reference>
  <reference>
    <citation>Liang L, Safran S, Gao Y, Sheha H, Raju VK, Tseng SC. Ocular demodicosis as a potential cause of pediatric blepharoconjunctivitis. Cornea. 2010 Dec;29(12):1386-91. doi: 10.1097/ICO.0b013e3181e2eac5.</citation>
    <PMID>20847679</PMID>
  </reference>
  <reference>
    <citation>Liu J, Sheha H, Tseng SC. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol. 2010 Oct;10(5):505-10. doi: 10.1097/ACI.0b013e32833df9f4. Review.</citation>
    <PMID>20689407</PMID>
  </reference>
  <reference>
    <citation>Gao YY, Xu DL, Huang lJ, Wang R, Tseng SC. Treatment of ocular itching associated with ocular demodicosis by 5% tea tree oil ointment. Cornea. 2012 Jan;31(1):14-7. doi: 10.1097/ICO.0b013e31820ce56c.</citation>
    <PMID>21955627</PMID>
  </reference>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 15, 2014</lastchanged_date>
  <firstreceived_date>July 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blepharitis</keyword>
  <keyword>Demodex</keyword>
  <keyword>Mites</keyword>
  <keyword>Tea Tree oil</keyword>
  <keyword>Terpinen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
